At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Akt Inhibitor MK2206 +2 moredrug
Likely dose
Akt Inhibitor MK2206 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of AKT Inhibitor MK2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation, or an AKT Mutation, and/or PTEN Loss/PTEN Mutation
In Brief
A Phase 2 clinical trial evaluating Akt Inhibitor MK2206, Laboratory Biomarker Analysis, and 1 other intervention for Recurrent Breast Carcinoma and 3 related conditions. Completed, enrolled 30 participants across 5 sites.
Detailed Summary
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with breast cancer cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartMar 2011
Primary CompletionAug 2014
TodayJul 2026
First PostedJan 17, 2011
Enrollment StartMar 1, 2011
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 15.5 years ago
Interventions
Akt Inhibitor MK2206drug
Given orally (PO) weekly, starting (dose 0) at 200 mg
Laboratory Biomarker Analysisother
Correlative studies
Pharmacological Studyother
Correlative studies